ESTRO Multidisciplinary Management of Breast Cancer 2017

LORD: Phase III Open Labeled Randomized Non-Inferiority Randomized Clinical Trial

MAIN OBJECTIVE : TO COMPARE THE ACTIVE SURVEILLANCE WITH STANDARD TREATMENT APPROACH (CONVENTIONAL ARM) IN PATIENTS WITH LOW- GRADE DCIS.

PRIMARY END-POINT: IPSILATERAL INVASIVE BREAST CANCER-FREE RATE AT 10 YEARS.

SECONDARY END-POINTS (BOTH TREATMENT ARMS):

♦ TIME TO IPSILATERAL DCIS GRADE II- III

♦ TIME TO CONTRALATERAL DCIS GRADE I-II-III ♦ TIME TO CONTRALATERAL INVASIVE BREAST CANCER ♦ TYPE OF FIRST EVENT FOR PRIMARY ENDPOINT ♦ DISTANT METASTASES AND DEATH DUE TO BREAST CANCER ♦ OVERALL SURVIVAL

♦ TIME TO FAILURE ♦ QUALITY OF LIFE ♦ COST-EFFECTIVENESS

8